We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$247M
AUM Growth
-$117M
Cap. Flow
-$139M
Cap. Flow %
-56.36%
Top 10 Hldgs %
58.38%
Holding
95
New
54
Increased
7
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
WST icon
West Pharmaceutical
WST
+$23M
2
MRK icon
Merck
MRK
+$13M
3
AXSM icon
Axsome Therapeutics
AXSM
+$12M
4
APLS
Apellis Pharmaceuticals
APLS
+$11.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$24.2M
2
ARGX icon
argenx
ARGX
+$23.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.7M
5
LLY icon
Eli Lilly
LLY
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.81%
2 Real Estate 0.3%
3 Industrials 0.1%
4 Financials 0.1%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WST icon
1
West Pharmaceutical
WST
$25.4B
$22.8M 9.24%
+97,084
New +$23M
LLY icon
2
Eli Lilly
LLY
$1.05T
$19.9M 8.06%
54,469
-50,701
-48% -$18M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.8B
$15.5M 6.27%
119,695
+24,250
+25% +$2.81M
AXSM icon
4
Axsome Therapeutics
AXSM
$11.9B
$15.4M 6.24%
+200,054
New +$12M
MRK icon
5
Merck
MRK
$315B
$14.1M 5.7%
+126,912
New +$13M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.5B
$12.9M 5.23%
+124,979
New +$11.7M
ASND icon
7
Ascendis Pharma A/S
ASND
$17.2B
$12.1M 4.9%
+99,215
New +$11.5M
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$11.5M 4.64%
+221,897
New +$11.8M
STVN icon
9
Stevanato
STVN
$5.22B
$10.3M 4.17%
574,037
-197,896
-26% -$3.28M
ATXS
10
DELISTED
Astria Therapeutics
ATXS
$9.7M 3.92%
651,330
+19,751
+3% +$204K
CLDX icon
11
Celldex Therapeutics
CLDX
$2.8B
$7.85M 3.17%
176,109
-62,460
-26% -$2.23M
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.7B
$7.66M 3.1%
+26,386
New +$2.58M
AKRO
13
DELISTED
Akero Therapeutics
AKRO
$7.06M 2.86%
128,851
-80,397
-38% -$3.44M
PCVX icon
14
Vaxcyte
PCVX
$8.1B
$5.44M 2.2%
113,477
+34,066
+43% +$1.34M
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.37M 2.17%
+141,466
New +$4.87M
ALT icon
16
Altimmune
ALT
$546M
$5.36M 2.17%
325,694
+168,391
+107% +$1.89M
NVCR icon
17
CALL
NovoCure
NVCR
$1.86B
$5.31M 2.15%
+72,400
New +$5.45M
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.2M 2.1%
243,079
+52,482
+28% +$1.12M
AVDL
19
DELISTED
Avadel Pharmaceuticals
AVDL
$4.9M 1.98%
+684,556
New +$4.8M
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.74M 1.92%
104,598
-46,936
-31% -$3.04M
INMD icon
21
InMode
INMD
$888M
$4.54M 1.84%
+127,242
New +$4.43M
FLNA
22
CALL
Filana Therapeutics
FLNA
$49.8M
$3.76M 1.52%
127,200
-162,100
-56% -$5.83M
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.56B
$3.68M 1.49%
93,364
-40,967
-30% -$1.49M
XFOR icon
24
X4 Pharmaceuticals
XFOR
$360M
$3.68M 1.49%
123,551
+40,084
+48% +$1.9M
GH icon
25
Guardant Health
GH
$20.4B
$3.55M 1.44%
130,448
-155,500
-54% -$7.12M
1
2 3 4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Tri Locum Partners held 95 positions worth $247M, down 32% from $364M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Tri Locum Partners withdrew a net $139M in Q4 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was Biogen, an estimated $24.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Tri Locum Partners opened a new position in West Pharmaceutical worth $22.8M.

  • Tri Locum Partners's largest Q4 2022 buy was West Pharmaceutical: 97,084 shares worth $22.8M.
  • Tri Locum Partners added most to Sarepta Therapeutics in Q4 2022, an estimated $2.81M increase.
  • Tri Locum Partners's biggest Q4 2022 reduction was argenx, cutting an estimated $23.5M.
  • Tri Locum Partners fully exited Biogen in Q4 2022, selling an estimated $24.2M.
  • Tri Locum Partners's ten largest holdings make up 58% of its $247M portfolio in Q4 2022.
  • Tri Locum Partners opened 54 new positions and closed 22 in Q4 2022.
  • Tri Locum Partners's portfolio value fell 32% quarter-over-quarter to $247M.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.